STC 1010
Alternative Names: STC-1010Latest Information Update: 08 May 2025
At a glance
- Originator Brenus Pharma
- Class Antineoplastics; Cancer vaccines; Immunotherapies; Tumour cell vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Colorectal cancer; Gastrointestinal cancer; Pancreatic cancer
Most Recent Events
- 23 Apr 2025 Brenus Pharma plans the first-in-human phase Ia/II BreAK-CRC trial for Colorectal cancer (Metastatic disease, Late-stage disease, Inoperable/unresectable, First-line therapy) (Parenteral) in France in June 2025 (NCT06934538)
- 08 Nov 2024 Pharmacodynamics data from a preclinical data in Colorectal cancer released by Brenus pharma
- 13 Jun 2024 The French National Health Authority reviewed the phase I/II BreAK-CRC trial protocol in pre-submission meeting